You are here

Researchers Find 413 Genes Associated With Schizophrenia

Genes Are Expressed from Early Pregnancy Through Adulthood

In a study of more than 100,000 people, researchers at the Icahn School of Medicine at Mount Sinai used a novel machine-learning method to identify 413 genetic associations with schizophrenia across 13 regions of the brain. By examining gene expression at the tissue level, researchers identified new genes associated with schizophrenia and were also able to pinpoint areas of the brain in which abnormal expression might occur.

Although it affects less than 2% of the population worldwide, schizophrenia is one of the main causes of disability. The disease has a major public health and socioeconomic impact, primarily because of hospital readmission rates and treatment costs.

The researchers used genome-wide association study findings together with transcriptomic imputation to identify schizophrenia-associated disease with tissue-level resolution. Genome-wide association studies examine differences at various points in a genetic code to see whether a variation occurs more frequently in those with a particular trait, such as schizophrenia. Transcriptomic imputation, a novel machine-learning technique, enables researchers to test associations between disease and gene expression in otherwise unreachable tissues, such as brain tissue.

Studying 40,299 people with schizophrenia and 62,264 matched controls, the researchers discovered that genes associated with schizophrenia are expressed throughout development–some during early stages of pregnancy, and others during adolescence or adulthood. They also discovered that different brain regions confer different risks for schizophrenia, and most associations stem from the dorsolateral prefrontal cortex.

Source: MedicalXpress, March 25, 2019

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial